t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis

Kidney International

Volumn 59, Issue 6, 2001, Pages 2146-2155

  Haraguchi, Masashi ^a   Border, Wayne A ^a   Huang, Yufeng ^a   Noble, Nancy A ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Fibrosis Research Laboratory   (United States)

Author keywords

Antifibrotic therapy; Fibrin; Metalloproteinase; Nephritic glomeruli; Tissue plasminogen activator; Transforming growth factor

Indexed keywords

ALTEPLASE; COLLAGEN TYPE 1; FIBRIN; FIBRONECTIN; LAMININ; MATRIX PROTEIN; METALLOPROTEINASE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GLOMERULONEPHRITIS; GLOMERULUS; MALE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEINURIA; RAT; SCORING SYSTEM;

EID: 0034999371     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.0590062146.x     Document Type: Article

References (60)

1. Border WA, Noble NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
2. Border WA, Okuda S, Nakamura T: Extracellular matrix and glomerular disease. Semin Nephrol 9:307-317, 1989
3. Border WA, Noble NA: Interactions of transforming growth factor-β and angiotensin I1 in renal fibrosis. Hypertension S31:181-188, 1998
4. Schnaper HW: Balanced between matrix synthesis and degradation: A determinant of glomerulosclerosis. Pediatr Nephrol 9:104-111, 1995
5. Fioretto P, Steffes MW, Sutherland DER, et al: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69-75, 1998
6. Stetler-Stevenson WG: Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 148: 1345-1350, 1996
7. Mignatti P: Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int 47(Suppl 49):S12-S14, 1995
8. Liotta LA, Goldfarb RH, Brundage R, et al: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 43:4629-4636, 1981
9. Mochan E, Keler T: Plasmin degradation of cartilage proteoglycan. Biochim Biophys Acta 800:312-315, 1984
10. Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP: Basement membrane type IV collagen degradation: Evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 50:5997-6001, 1990
11. He C, Wilhelm SM, Pentland AP, et al: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 86:2632-2636, 1989
12. Nagase H, Enghild JJ, Suzuki K, Salvesen G: Stepwise activation mechanism of the precursor of matrix metalloproteinase 3 (stromolysin) by proteinases and (4-aminophenyl) mercuric acetate. Biochemistry 29:5783-5789, 1990
13. Ramos-Desimone N, Hahn-Dantona E, Shipley J, et al: Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/ stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274:13066-13076, 1999
14. Baricos WH, Cortez SL, El-Dahr SS, Schnaper HW: ECM degradation by cultured human mesangial cells is mediated by a PA/ plasmin/MMP-2 cascade. Kidney Int 47:1039-1047, 1995
15. Lacave R, Rondeau E, Ochi S, et al: Characterization of a plasminogen activator and its inhibitor in human mesangial cells. Kidney Int 35:806-811, 1989
16. Glass WF II, Kreisberg JI, Troyer DA: Two-chain urokinase, receptor, and type 1 inhibitor in cultured human mesangial cells. Am J Physiol 264:F532-F539, 1993
17. Angles-Cano E. Rondeau E, Delarue F, et al: Identification and cellular localization of plasminogen activators from human glomeruli. Thromb Haemost 54:688-692, 1985
18. Ranby M: Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 704:461-469, 1982
19. Aya N, Yoshioka K, Murakami K, et al: Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis. J Pathol 166:289-295, 1992
20. Noble NA, Border WA: Angiotensin II in renal fibrosis: Should TGF-β rather than blood pressure be the therapeutic target? Semin Nephrol 17:455-466, 1997
21. Baricos WH, Cortez SL, Deboisblanc M, Xin S: Transforming growth factor-β is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 10: 790-795, 1999
22. Tomooka S, Border WA, Marshall BC, Noble NA: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42:1462-1469, 1992
23. Marti HP, Kashgarian M, Lee L, Lovett DH: Transforming growth factor-β1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am J Pathol 144:82-94, 1994
24. Poncelet AC, Schnaper HW: Regulation of human mesangial cell collagen expression by transforming growth factor-β. Am J Physiol 275:F458-F466, 1998
25. Sato Y, Fujimoto S, Hamai K, Eto T: Serial alterations of glomerular matrix-degrading metalloproteinase activity in anti-thymocyte-induced glomerulonephritis in rats. Nephron 78:195-200, 1998
26. Kagami S, Kuhara T, Okada K, et al: Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 51:664-671, 1997
27. Peters H, Border WA, Noble NA: Targeting TGF-β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54:1570-1580, 1998
28. Peters H, Border WA, Noble NA: Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int 57: 992-1001, 2000
29. Oikawa T, Freeman M, Lo W, et al: Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51:164-172, 1997
30. Ma L-J, Nakamura S, Whitsitt JS, et al: Regression of vascular and renal sclerosis in aging by angiotensin II type I receptor antagonist-induced decrease in plasminogen activator inhibitor-1. Kidney Int 58:2425-2436, 2000
31. Yamamoto T, Noble NA, Cohen AH, et al: Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int 49:461-469, 1996
32. Shihab FS, Yamamoto T, Nast CC, et al: Transforming growth factor-β and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 6:286-294, 1995
33. Yamamoto T, Noble NA, Miller DE, et al: Increased levels of transforming growth factor-β in HIV-associated nephropathy. Kidney Int 55:579-592, 1999
34. Ehrlich HJ, Klein Gebbink R, Keijer J, et al: Alteration of serpin specificity by a protein cofactor: Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 265:13029-13035, 1990
35. Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 86:453-462, 1990
36. Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int 45:916-927, 1994
37. Fort P, Marty L, Piechaczyk M, et al: Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 13:1431-1442, 1985
38. Derynck R, Jarrett A, Chen EY, Goeddel DV: The murine transforming growth factor-β precursor. J Biol Chem 261:4377-4379, 1986
39. Schwarzbauer JE, Tamkun JW, Lemischka IR, Hynes RO: Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell 35:421-431, 1983
40. Zeheb R, Gelehrter TD: Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 73:459-468, 1988
41. Lyons RM, Keski-Oja J, Moses HL: Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J Cell Biol 106:1659-1665, 1988
42. Lelièvre Y, Bouboutou R, Boiziau J, et al: Low molecular weight, sequence based, collagenase inhibitors selectively block the interaction between collagenase and TIMP (tissue inhibitor of metalloproteinases). Matrix 10:292-299, 1990
43. Abboud HE: Growth factors in glomerulonephritis. Kidney Int 43: 252-267, 1993
44. Sebecova K, Dammrich J, Fierlbeck W, et al: Systemic treatment with proteolytic enzymes in rat models of nonimmune mediated renal diseases. Int J Immunother 13:79-83, 1997
45. Emancipator SN, Chintalacharuvu SR, Urankar Nagy N, Stauder G: Oral enzymes in different animal models of glomerulonephritis. Int J Immunother 13:97-103, 1997
46. Heidland AS, Paczek K, Teschner L, et al: Renal fibrosis: Role of impaired proteolysis and potential therapeutic strategies. Kidney Int 52(Suppl 62):S32-S35, 1997
47. Lehmann PV: Immunomodulation by proteolytic enzymes. Nephrol Dial Transplant 11:953-955, 1996
48. Zoja C, Corna D, Macconi D, et al: Tissue plasminogen activator therapy of rabbit nephrotoxic nephritis. Lab Invest 62:34-40, 1990
49. Malliaros J, Holdsworth SR, Wojta J, et al: Glomerular fibrinolytic activity in anti-GBM glomerulonephritis in rabbits. Kidney Int 44:557-564, 1993
50. Border WA: Anticoagulants are of little value in the treatment of renal disease. Am J Kidney Dis 3:308-312, 1984
51. Lawrence DA: Transforming growth factor-β: An overview. Kidney Int 47(Suppl 49):S19-S23, 1995
52. Yehualaeshet T, O'Connor R, Green-Johnson J, et al: Activation of rat alveolar macrophage-derived latent transforming growth factor β-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am J Pathol 155:841-851, 1999
53. Johnson RJ, Couser WG, Alpers CE, et al: The human neutrophil serine proteinases, elastase and cathepsin G, can mediate glomerular injury in vivo. J Exp Med 168:1169-1174, 1988
54. Kitamura M, Shirasawa T, Maruyama N: Gene transfer of metalloproteinase transin induces aberrant behavior of cultured mesangial cells. Kidney Int 45:1580-1586, 1994
55. Turck J, Pollock AS, Lee LK, et al: Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 271:15074-15083, 1996
56. Turck J, Pollock AS, Lovett DH: Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney Int 51: 1397-1400, 1997
57. Steinmann-Niggli K, Ziswiler R, Kung M, Marti HP: Inhibition of matrix metalloproteinases attenuates anti-Thy 1.1 nephritis. J Am Soc Nephrol 9:397-407, 1998
58. Ono T, Muso E, Suyama K, et al: Intraglomerular deposition of intact cross-linked fibrin in Ig A nephropathy and Henoch-Schonlein purpura nephritis. Nephron 74:522-528, 1996
59. McCutcheon J, Evans B, D'Cruz DP, et al: Fibrin deposition inn SLE glomerulonephritis. Lupus 2:99-103, 1993
60. Loscalzo J, Braunwald E: Tissue plasminogen activator. N Engl J Med 319:925-931, 1988